NewsRoom Articles - Page 5 of 202

FridayMar 21, 2025 10:00 am

New Study Shows ‘Viral Mimicry’ Could Transform Glioblastoma Treatment

Glioblastoma continues to be one of the most challenging cancers to treat as it resists even the latest innovations in immunotherapy. Now, a new study conducted by a team at the Sylvester Comprehensive Cancer Center at the University of Miami suggests that, when a specific protein is suppressed, an antiviral immune response increases the effectiveness of immune checkpoint inhibitors. This discovery not only opens the door to a novel way to treat glioblastoma but also suggests that the protein in question, ZNF638, could be a valuable biomarker as treatment teams customize immunotherapy for specific patients. The research findings appeared in…

ThursdayMar 20, 2025 10:00 am

Study Shows Bioengineered Materials Can Treat Oral Mucositis

New research that appeared in the journal Oncotarget has opened the door to a new way to approach the treatment of oral ulcers induced by chemotherapy. This debilitating and painful side effect of cancer treatment lowers the quality of life of patients undergoing chemotherapy, but oral mucositis remains an unmet medical need. The study was conducted by a joint team from the Center for Research in Physics in Brazil and others from Rio de Janeiro Federal University. The lead author was Ana Chor. They sought to examine how effective an electrospun poly membrane (PLGA) was in accelerating tissue regeneration in…

ThursdayMar 20, 2025 9:00 am

Adageis on Track to Exceed Q1 Growth Target, Expanding Healthcare AI Platform

Adageis is surpassing its Q1 2025 growth targets, reflecting expanding market demand, with investment focused on team expansion, financial infrastructure, and AI development. Adageis’ patented AI-driven platform, already covering over 250,000 patient lives, optimizes quality healthcare for patients and revenue for healthcare providers. The company projects 580,000 patient lives covered by the end of Q2 2025. Adageis, a healthcare technology company reshaping patient care through flexible AI-centric software solutions for healthcare organizations, is set to exceed its Q1 2025 growth expectations as its AI-powered platform continues to gain traction in the healthcare sector. The company now covers more than 250,000…

WednesdayMar 19, 2025 9:00 am

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Delivers Significant Survival Benefits in New Analyses of Healey ALS Platform Trial Data

Clene's CNM-Au8® treatment was demonstrated to improve survival in ALS patients by up to 14.8 months. The findings come from a post hoc analysis of the HEALEY ALS Platform Trial, comparing CNM-Au8 to a concurrently enrolled control. Strong survival benefit was observed in patients meeting the planned criteria for Clene’s upcoming Phase 3 RESTORE-ALS trial. The company is preparing to submit a New Drug Application (“NDA”) to the FDA later this year for potential accelerated approval, and further regulatory discussions and a confirmatory Phase 3 trial are planned for mid-2025. Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine…

TuesdayMar 18, 2025 10:00 am

The Clock is Ticking if You Wish to Reconsider Your Medicare Advantage Plan

The open enrollment period for Medicare Advantage (MA) is on until the end of March. If you have been thinking about changing your medical plan, time is running out and you need to act fast. However, your decision shouldn’t be a rushed one as many considerations need to be weighed before you make any decisions. For starters, why would anyone think of changing their MA plan at this time? Many people have their preferred doctors or medical specialists and when those professionals are no longer in the preferred network of their plan provider, it is understandable to switch plans and…

FridayMar 14, 2025 10:00 am

The Brain’s ‘Cleanup Crew’ Could Hold the Key to Alzheimer’s Treatment, Study Shows

A new study conducted by a team at Northwestern University suggests that the brain’s immune cells can be enhanced so that they remove amyloid beta plaques more effectively. Amyloid beta plaques are the toxic proteins that form sticky clumps leading to the development of neurodegenerative diseases like Alzheimer’s. This new discovery could trigger a revolution in the thinking behind current AD treatments and future varieties may benefit from the insights obtained from this study. Efforts have been undertaken to develop AD vaccines, but patients have serious immune responses to these drugs which can cause potentially life-threatening inflammation in the brain.…

FridayMar 14, 2025 9:00 am

Adageis to Launch Series A Funding Round, Seeking $10M in Growth Capital

Adageis is opening a Series A funding round, capital raise, aiming to raise $10 million for growth and expansion. The company previously closed a $2 million seed round in Q4 2024 to enhance operations and market reach. Adageis expects to exceed growth targets for Q1 2025, with strong market adoption of its AI-powered platform designed to streamline healthcare operations, optimize revenue, and improve patient care outcomes. The company has cut onboarding time from four weeks to one week, accelerating customer acquisition and revenue growth. Adageis, a healthcare technology company reshaping patient care through flexible AI-centric software solutions for healthcare organizations,…

ThursdayMar 13, 2025 10:00 am

Why it is Crucial to Prepare Healthcare Data for Use in AI Models

The rate at which AI is being integrated in healthcare is accelerating. However, data quality is often lacking, and this reduces the effectiveness of many AI solutions tailored to the healthcare industry. Given that healthcare data is often siloed, the vast majority of this data is unstructured. This can pose challenges in the use of this data for AI models since the insights extracted could be biased or have other defects. Data needs to be consistent in the way it is presented, its quality must be high and the formats need to be standardized. Otherwise, the data could be misinterpreted…

ThursdayMar 13, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) Is ‘One to Watch’

Soligenix has multiple late-stage assets with orphan and fast-track designations, providing a clear regulatory pathway toward potential approvals. The company’s pipeline has a total addressable market exceeding $2 billion, spanning rare diseases, inflammation, and biothreat applications. Soligenix has benefited from significant non-dilutive government funding, which reduces operational expenses and financial risk while supporting its public health initiatives. The company is well-positioned for multiple development and regulatory catalysts, and commercial milestones, with lead candidates in cutaneous T-cell lymphoma, psoriasis, oral mucositis, and Behçet’s disease. Soligenix is led by an experienced management team with a strong track record of success. Soligenix (NASDAQ:…

WednesdayMar 12, 2025 9:00 am

Clene Inc. (NASDAQ: CLNN) to Present CNM-Au8(R) Updates at 37th Annual Roth Conference

The 37th Annual Roth Conference, to be held March 16-18 in Dana Point, California, will showcase the broadest group of companies in the event’s history, with senior executives from approximately 500 companies across various industries, including business services, consumer, healthcare, insurance, sustainability and technology, media and entertainment. Clene’s management will participate in a virtual fireside chat at 9:20 a.m. PST on March 18, as well as one-on-one investor meetings during the event. During the fireside chat and in investor meetings, the company will detail recent achievements and next steps for lead drug candidate CNM-Au8 for ALS and MS. Clene Inc.…